A Phase 1/2 interventional study of SonoCloud-4 (SC4) device in Amyotrophic Lateral Sclerosis and Charcot Disease, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-10.
Sponsored by Assistance Publique - Hôpitaux de Paris · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Amyotrophic Lateral Sclerosis by Assistance Publique - Hôpitaux de Paris — 7 open to participants now, 7 under way, none of them phase 3. Amyotrophic Lateral Sclerosis · Assistance Publique - Hôpitaux de Paris.
Among the 21 studies in Amyotrophic Lateral Sclerosis by Assistance Publique - Hôpitaux de Paris, this one is the 10th largest by planned enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2026, is the only one in phase 1/2, and was the 21st registered.
981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.
Browse Amyotrophic Lateral Sclerosis studies →7 of the 21 studies in Amyotrophic Lateral Sclerosis by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+ · Healthy volunteers
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–80
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+ · Healthy volunteers
Assistance Publique - Hôpitaux de Paris
Ages 18+
By country, each count listing its studies:
Of the 194 Amyotrophic Lateral Sclerosis studies recruiting now, 119 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 56 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 3
First in 2002; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 23 is below the median of 38 across 664 interventional studies indexed under Amyotrophic Lateral Sclerosis.
Median enrollment 30 across the 17 interventional studies, 200 across the 4 observational. Of the 10 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.
1 of the studies in Amyotrophic Lateral Sclerosis by Assistance Publique - Hôpitaux de Paris that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06021938Assistance Publique - Hôpitaux de ParisAlleviating Persistent Dyspnea in Amyotrophic Lateral Sclerosis Patients Treated With Non-Invasive Ventilation Through Immersive Virtual Reality | 2027-04-04 |
Add it to your calendar (.ics) → With an account.
Among the 21 studies in Amyotrophic Lateral Sclerosis by Assistance Publique - Hôpitaux de Paris, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is proof-of-concept, single-arm, single-center study to assess the safety and explore the efficacy of repeated US transient disruptions of the blood-brain barrier (BBB) in Amyotrophic Lateral Sclerosis (ALS).
Phase 1:
The primary objective is to assess the safety of ultrasound induced BBB opening in the upper motor neuron area and adjacent supplementary motor area in adult patients with ALS, as assessed by adverse events frequency and severity during study (incidence of AE summarized by system organ class and/or preferred term and severity) based on the Common Terminology Criteria for Adverse Events, version 5.0 A run-in period of 12 weeks between inclusion and baseline will take place for each patient in order to evaluate precisely disease progression rate, disease severity and to collect concomitant medication. After this run-in period, the patient will be implanted with the SC4 device (baseline visit). The first sonication session will be performed two weeks after implantation. A total of 9 sonications, with no concomitant drug administration, will be performed over a period of 24 weeks.
Phase 2a:
Based on the safety outcome of the Phase 1, an expansion cohort will open to assess the first signal of efficacy of the US transient disruptions of the BBB in ALS. The primary objective will be to assess the first signal of efficacy of the procedure on disease progression over 26 weeks evaluated by the change from baseline to week 26 of neurofilament light (NfL) levels in blood.The Phase 2a will continuously include 11 additional patients. Patients will be treated according to the same schedule as in phase 1
The blood-brain barrier (BBB) significantly limits drug delivery to the central nervous system and contributes to the difficulty of developing effective treatments for Amyotrophic Lateral Sclerosis (ALS). Low intensity pulsed ultrasound can be used to transiently disrupt the BBB without tissue damage, to enhance drug penetration. Ultrasound-induced BBB disruption can also modulate the immune response in the central nervous system and may thus also be therapeutic by itself in ALS by stimulating innate and cellular immune responses.
This is proof-of-concept, single-arm, single-center, phase 1/2a study to assess the safety and explore the efficacy of repeated US transient disruptions of the BBB in ALS.
The primary objective of the phase 1 study is to assess the safety of ultrasound induced BBB opening in the upper motor neuron area and adjacent supplementary motor area in adult patients with ALS. Based on the safety outcome of the phase 1, an expansion cohort will open to assess the first signal of efficacy of the US transient disruptions of the blood-brain barrier in ALS. The inclusion visit will take place 12 weeks before the baseline visit. Clinical evaluation of motor function, pulmonary function tests and brain MRI (for future device positioning and safety comparison with post explantation MRI) will be performed, and implantation will be planned after a run-in period of 12 weeks.
The baseline visit corresponds to the implantation of SC4 device and the patient will be hospitalized in the Neurosurgery department. Clinical evaluation (ALSFRS-R, manual muscle testing), pulmonary function tests and ALSAQ-5 quality of life evaluation will be performed before implantation as well as blood samplings for serum NfL and baseline immune status. The implantation will be performed under local anesthesia.
After 2 weeks, the first ultrasound session visit will be performed in day care hospital in the Neurosurgery department. The connection between the implant and the external generator will be made using a transdermal needle.
After the first sonication session only, a brain MRI will be performed with Gadolinium injection, to confirm BBB opening. Pre and post-sonication dosing of serum NfL and markers of BBB disruption will also be performed after the first sonication visit.
Eight additional ultrasound session visits will be performed at three-week intervals. At the fifth sonication visit (W14), motor function evaluation (ALSFRS-R and manual muscle testing), pulmonary function testing, blood samplings for serum NfL and ALSAQ-5 QOL evaluation will be performed before sonication.
At the last sonication (W26), clinical evaluation (ALSFRS-R, Manual muscle testing), pulmonary function test and ALSAQ-5 quality of life evaluation will be performed before sonication as well as blood samplings for serum NfL and pre-explantation preoperative laboratory blood tests. After the last ultrasound session, the patient will be followed up for a total of 12 weeks.
The explantation visit will take place at week 28. Explantation will be performed in a dedicated surgical procedure under local anesthesia: skin opening, device removal, no dura matter opening. Before explantation motor function evaluation will be performed. After explantation, neurological evaluation and brain MRI will be performed for safety evaluation. The last visit is planned at week 38 and will be performed by the neurology team as an outclinic visit (neurological examination, evaluation of motor function, ALSAQ-5 quality of life evaluation).
After this last visit, patients will resume their routine follow-up. Vital status and date of last known contact will be documented at the end of the study for all participants (at the last visit of the last patient included).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Repeated US transient disruptions of the blood-brain barrier
Device: SonoCloud-4 (SC4) device
Implantation of SC4 device and 9 Blood Brain Barrier opening sessions by ultrasound without any associated drug
Phase 1 : Adverse events frequency and severity during study to assess the safety of ultrasound induced BBB opening in the upper motor neuron area and adjacent supplementary motor area
incidence of AE summarized by system organ class and/or preferred term and severity based on the Common Terminology Criteria for Adverse Events, version 5.0
Time frame: from inclusion up to 50 weeks
Phase 2a : Neurofilament light (NfL) levels in blood to assess the first signal of efficacy of the procedure on disease progression
Change from baseline to week 26 of neurofilament light (NfL) levels in blood
Time frame: from baseline to 26 weeks
ALSFRS-R score (ALS functional rating scale (revised),
Change from baseline to week 26 of ALSFRS-R ( Amyotrophic Lateral Sclerosis Functional Rating Scale) score. The total score ranges from 0 (total loss of function) to 48 (fully preserved function).
Time frame: from baseline to 26 weeks
ALSFRS-R slope
Change in the slope of the decline of the ALSFRS-R (Amyotrophic Lateral Sclerosis Functional Rating Scale) during treatment period vs pre-treatment period. The total score ranges from 0 (total loss of function) to 48 (fully preserved function).
Time frame: from baseline to 26 weeks
Muscle strength
Change from baseline to week 26 in muscle strength, evaluated by manual muscle testing (Medical Research Council score)
Time frame: from baseline to 26 weeks
Neurofilament light (NfL)
Change from baseline to week 26 of neurofilament light (NfL) levels in blood (biomarker for neurodegeneration and clinically validated prognostic biomarker for ALS)
Time frame: from baseline to 26 weeks
QOL (Quality of Life)
Change from baseline to week 26 on global score of QOL (Quality of Life) evaluated with ALSAQ-5 (amyotrophic lateral sclerosis assessment questionnaire) (a disease-specific patient self-report health status specifically used to measure the subjective well-being of patients with ALS). Each item is scored from 0 to 4, and the values are then converted to an overall scale of 0 to 100, where 0 represents the best health status and 100 the most impaired.
Time frame: 26 weeks
ALSFRS-R score
Change from baseline to week 8 of ALSFRS-R (Amyotrophic Lateral Sclerosis Functional Rating Scale) score. The total score ranges from 0 (total loss of function) to 48 (fully preserved function).
Time frame: from baseline to weeks 8
ALSFRS-R score (Amyotrophic Lateral Sclerosis Functional Rating Scale)
Change from baseline to week 20 of ALSFRS-R score ((Amyotrophic Lateral Sclerosis Functional Rating Scale). The total score ranges from 0 (total loss of function) to 48 (fully preserved function).
Time frame: from baseline to weeks 20
Overall Survival (OS)
Overall Survival (OS) defined as time from baseline to death, compared to a control group from an external placebo control arm from PRO-ACT database (Pooled Resource Open-Access ALS Clinical Trials)
Time frame: from baseline to 12 months after the last inclusion
Neurofilament light (Nfl)
Change in Nfl blood levels from pre to post the first sonication (W2) to confirm BBB opening at the first sonication
Time frame: From baseline to week 2
protein S100β, Aquaporin-4 and NSE
Change of blood level of protein S100β, Aquaporin-4 and NSE from pre to post the first sonication (W2 to confirm BBB opening at the first sonication)
Time frame: From baseline to week 2
gadolinium enhancement on MRI
Gadolinium enhancement during MRI performed after the first sonication (Week2) to confirm BBB opening at the first sonication
Time frame: From baseline to week 2
Plan to share: Yes — The procedures carried out with the French data privacy authority (CNIL, Commission nationale de l'informatique et des libertés) do not provide for the transmission of the database, nor do the information and consent documents signed by the patients. Consultation by the editorial board or interested researchers of individual participant data that underlie the results reported in the article after deidentification may nevertheless be considered, subject to prior determination of the terms and conditions of such consultation and in respect for compliance with the applicable regulations.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Beginning 3 months and ending 3 years following article publication. Requests out of these time frame can also be submitted to the sponsor
Access criteria: Researchers who provide a methodologically sound proposal
No publications or documents are linked to this record.
Started Jul 2026 (actual). Primary completion is estimated for Jul 2030, 48 months after the start.
Of 36 phase 1/2 interventional studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 57. This study's planned 48 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Amyotrophic Lateral Sclerosis →
Assistance Publique - Hôpitaux de Paris →